Cabaletta Bio
Yahoo Finance • 3 days ago
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering s... Full story
Yahoo Finance • 2 months ago
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in the RESET™ clinical development progra... Full story
Yahoo Finance • 4 months ago
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces market skepticism
Cabaletta Bio, Inc. (NASDAQ:CABA), with a market capitalization of $106.17 million, is at the forefront of developing CAR-T therapies for autoimmune diseases, presenting a unique investment opportunity in the biotechnology sector. Accordin... Full story
Yahoo Finance • 4 months ago
Cabaletta Bio Launches Public Offering Of Stock And Warrants
(RTTNews) - Cabaletta Bio, Inc. (CABA), a clinical-stage biotech firm developing targeted cell therapies for autoimmune diseases, has initiated an underwritten public offering of its common stock and accompanying warrants. Certain investo... Full story
Yahoo Finance • 4 months ago
Cabaletta Bio announces pricing of public offering of securities; shares decline over 28%
* Cabaletta Bio (NASDAQ:CABA [https://seekingalpha.com/symbol/CABA]) announced on Wednesday the pricing of an underwritten public offering consisting of 39.2 million shares of its common stock and accompanying warrants to purchase an agg... Full story
Yahoo Finance • 4 months ago
Cabaletta Bio Announces Pricing of Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies desi... Full story
Yahoo Finance • 4 months ago
Cabaletta Bio Announces Proposed Public Offering of Securities
PHILADELPHIA, June 11, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies desi... Full story
Yahoo Finance • 4 months ago
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained throughout the follow-up period in all responding pati... Full story
Yahoo Finance • 4 months ago
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients w... Full story
Yahoo Finance • 6 months ago
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2... Full story
Yahoo Finance • 8 months ago
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
– Clinical efficacy continued to deepen over time with three SLE patients in DORIS remission, the first LN patient achieving complete renal response, and the first dermatomyositis patient maintaining a major TIS improvement; each of these... Full story
Yahoo Finance • 8 months ago
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the first lupus clinical site actively recruiting patients – – Expanded CABA-201 clinical develo... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
– First cleared CD19-CAR T IND application for generalized myasthenia gravis announced in the U.S. and fourth IND clearance for CABA-201 across a broad range of autoimmune diseases – – Clearance expands the clinical development of CABA-20... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201
– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis features parallel cohort design and the same starti... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune disea... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseas... Full story
Yahoo Finance • 2 years ago
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – – Partnership for CABA-201 builds on existing manufac... Full story
